New pill aims to reboot immune system to fight advanced cancer
NCT ID NCT06923761
Summary
This study is testing a new oral drug, GRWD5769, for people with advanced solid cancers that have spread or returned. The main goal is to see if the drug is safe and tolerable, both by itself and when combined with an existing immunotherapy. Researchers want to see if blocking a specific enzyme can help the immune system better recognize and attack cancer cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID MALIGNANCY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Alfred Health
RECRUITINGMelbourne, Australia
-
Austin Health
RECRUITINGHeidelberg, Australia
-
Blacktown Hospital
RECRUITINGBlacktown, Australia
-
Cancer Care Wollongong
RECRUITINGWollongong, Australia
-
Centre Eugène Marquis
RECRUITINGRennes, France
-
Centre Léon Bérard
RECRUITINGLyon, France
-
Christie NHS Foundation Trust
RECRUITINGManchester, United Kingdom
-
Clatterbridge Cancer Centre
RECRUITINGLiverpool, United Kingdom
-
Clinica Universitaria de Navarra Madrid
RECRUITINGMadrid, Spain
-
Clinica Universitaria de Navarra Pamplona
RECRUITINGPamplona, Spain
-
GenesisCare Research
WITHDRAWNAdelaide, Australia
-
Hammersmith Hospitals NHS Trust
RECRUITINGLondon, United Kingdom
-
Hospital Universitario Vall d'Hebrón (VHIO)
RECRUITINGBarcelona, Spain
-
Hospital Universitario Virgen de la Victoria
RECRUITINGMálaga, Spain
-
ICANS - Institut de Cancérologie Strasbourg
RECRUITINGStrasbourg, France
-
INCLIVA-Hospital Clínico Universitario de Valencia
RECRUITINGValencia, Spain
-
IUCT Oncopole - Institut Claudius Regaud
RECRUITINGToulouse, France
-
Institut Gustave Roussy
RECRUITINGVillejuif, France
-
Institut Paoli-Calmettes
RECRUITINGMarseille, France
-
Institut de Cancérologie de l'Ouest (ICO)
RECRUITINGSaint-Herblain, France
-
Kinghorn Cancer Centre (KCC)
RECRUITINGDarlinghurst, Australia
-
Mater Research
RECRUITINGSouth Brisbane, Australia
-
Newcastle Upon Tyne Hospital
RECRUITINGNewcastle, United Kingdom
-
Royal Free Hospital
RECRUITINGLondon, United Kingdom
-
START Barcelona - Hospital HM Nou Delfos
RECRUITINGBarcelona, Spain
-
START Madrid - Centro Integral Oncológico Clara Campal (HM CIOCC)
RECRUITINGMadrid, Spain
-
START Madrid - Hospital Universitario Fundacion Jimenez Diaz
RECRUITINGMadrid, Spain
-
Southern Oncology Clinical Research Unit (SOCRU)
RECRUITINGBedford Park, Australia
-
Western General Hospital
RECRUITINGEdinburgh, United Kingdom
Conditions
Explore the condition pages connected to this study.